[Form 4] MADRIGAL PHARMACEUTICALS, INC. Insider Trading Activity
Rhea-AI Filing Summary
Madrigal Pharmaceuticals director Paul A. Friedman reported an option exercise and small share sale. On January 9, 2026, he exercised a stock option for 280 shares of common stock at $15.80 per share, then sold 280 shares of common stock at a weighted average price of $551.2414 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, he directly owned 187,164 shares of Madrigal common stock. The filing also notes 655,540 shares held indirectly through SQN LLC, an entity for which he and his spouse are managing members, with a disclaimer that he only benefits to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
FAQ
What insider transaction did Madrigal (MDGL) disclose in this Form 4?
The Form 4 reports that director Paul A. Friedman exercised a stock option for 280 shares at $15.80 per share and sold 280 shares of Madrigal common stock at a weighted average price of $551.2414 per share on January 9, 2026.
Was the MDGL insider sale made under a Rule 10b5-1 trading plan?
Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Paul A. Friedman on September 10, 2025.
How many Madrigal (MDGL) shares does Paul A. Friedman own after the reported transactions?
Following the reported transactions, Paul A. Friedman directly owned 187,164 shares of Madrigal common stock and had an additional 655,540 shares reported as indirectly held through SQN LLC.
What is the nature of Paul A. Friedman’s indirect ownership in MDGL through SQN LLC?
The filing notes that Paul A. Friedman and his spouse are managing members of SQN LLC. He disclaims beneficial ownership of the shares held by SQN LLC except to the extent of his pecuniary interest.
What happened to the stock option reported in the Madrigal (MDGL) Form 4?
The Form 4 shows a stock option for 280 shares of Madrigal common stock with an exercise price of $15.80. On January 9, 2026, it was exercised in full, leaving 0 derivative securities of that option reported as beneficially owned afterward.
Over what price range were the MDGL shares sold in this insider transaction?
The filing explains that the $551.2414 figure is a weighted average; the 280 shares were sold in multiple trades at prices ranging from $551.24 to $551.25 per share.